ReviewVox sanguinis2026
Pathogen inactivation of red cell concentrates and whole blood: I. History, technologies and in vitro product preservation studies.
Review in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathogen Reduction of Transfused Blood Components-The End of the Beginning Rather than the Beginning of the End.Pathogens (Basel, Switzerland) · 2026Review
- Pathogen inactivation of red cell concentrates and whole blood: II. In vivo human recovery studies, clinical trials and future directions.Vox sanguinis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The application of technologies to inactivate pathogens in pooled plasma products is nowadays the standard. The number of blood centres applying these technologies to platelet concentrates is steadily increasing. However, pathogen inactivation (PI) of red cell concentrates and whole blood (WB) is challenging, as the haemoglobin-containing red cells quench light, and therefore require a different approach. Three technologies are currently under active development: S-303 (Intercept), UV-C (Theraflex) and riboflavin/UV (Mirasol). The S-303 technology is used for PI of red cell concentrates and has seen significant technical and clinical development in the last decade. Using this technology, red cell both ATP and haemolysis levels conform to objective requirements. For the UV-C technology, only one publication is available showing satisfactory quality of treated red cell concentrates in vitro. Lastly, the riboflavin and UV light technology is used on WB, and the in vitro data show room for improvement for red cell ATP and haemolysis levels. Part II of this review focuses on recovery studies and clinical trials that have been performed using pathogen-inactivated red cell concentrates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.